GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Valbiotis ALVAL.PA · EUR

Health Care · Euronext Paris · 🇫🇷 France

Compare

0.63

-2.03%

Close of 9 Nov 2026, in EUR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Popular Bitcoin Ethereum Nvidia Apple S&P 500 Gold EUR/USD US 10Y

About Valbiotis

Its shares trade on Euronext Paris under the ticker ALVAL.PA. It has been listed since 7 June 2017. In the fiscal year to 31 December 2025, it reported revenue of €905,000 and a net loss of €9.4m. At that date it held total assets of €14.4m and shareholders' equity of €7.0m.

Valbiotis SA develops products and candidate drugs designed to prevent metabolic diseases. The company is headquartered in Perigny, Nouvelle-Aquitaine. The company went IPO on 2017-06-07. The firm specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. The company seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The firm prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. The company provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
7 Jun 2017
Employees
36
Website
valbiotis.com ↗

Leadership

Pay as last reported

  • Dr. Laurent LevyIndependent Chairman of the Supervisory Board, since 2017
  • Dr. Sebastien PeltierChief Executive Officer, Co-Founder, Member of the Executive Committee€259,500
  • Mr. Stanislas SordetChief Financial Officer, Head - Administration and Finance, Member of the Executive Committee
  • Mr. Sebastien BessyChief Operating Officer, Head - Marketing and Commercial Operations, Member of the Executive Committee€104,000
  • Mr. Pascal SirventChief Scientific Officer, Member of the Executive Board, since 2023€193,600
  • Ms. Murielle CazaubielCMO, Head - Medical, Regulatory and Industrial Affairs, Member of the Executive Committee, since 2024€206,700
  • Ms. Agnes TixierIndependent Member of the Supervisory Board€99,900
  • Mr. Jean ZetlaouiIndependent Member of the Supervisory Board€99,900

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Valbiotis SA has a strong product portfolio consisting of innovative health solutions.
  • The company has a dedicated and experienced team with strong expertise in the field of biotechnology.
  • Valbiotis SA has established partnerships with reputable companies, ensuring access to distribution channels and potential collaborations.

Weaknesses

  • Valbiotis SA operates in a highly competitive market, which poses challenges in terms of market share and pricing.
  • The company relies heavily on the success of its research and development efforts, making it susceptible to uncertainties.
  • Valbiotis SA may face financial constraints in scaling up production or expanding its product line.

Opportunities

  • The growing demand for natural and preventive healthcare products presents a significant opportunity for Valbiotis SA to expand its customer base.
  • Valbiotis SA can leverage emerging markets and global trends towards holistic health and wellness.
  • The increasing interest in personalized nutrition provides an avenue for Valbiotis SA to develop tailored products and services.

Threats

  • Valbiotis SA is subject to strict regulations and compliance requirements in the healthcare industry, which could impact its operations.
  • The presence of substitute products and alternative therapies may pose a threat to Valbiotis SA's market position.
  • Economic downturns or market fluctuations can impact consumer spending habits, potentially affecting the demand for Valbiotis SA's products.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.